OpenLB
Open Library of Bioscience
Advanced Search
Cell & bioscience
2020;10 59.

Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells.

Thanakorn Pungsrinont, Malika Franziska Sutter, Maren C C M Ertingshausen, Gopinath Lakshmana, Miriam Kokal, Amir Saeed Khan, Aria Baniahmad
Author Information
  1. Thanakorn Pungsrinont: 1Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740 Jena, Germany.
  2. Malika Franziska Sutter: 1Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740 Jena, Germany.
  3. Maren C C M Ertingshausen: 1Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740 Jena, Germany.
  4. Gopinath Lakshmana: 1Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740 Jena, Germany.
  5. Miriam Kokal: 1Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740 Jena, Germany.
  6. Amir Saeed Khan: 1Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740 Jena, Germany.
  7. Aria Baniahmad: 1Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740 Jena, Germany.
PMID: 32351687 DOI: 10.1186/s13578-020-00422-2

Abstract

BACKGROUND: The benefit of inducing cellular senescence as a tumor suppressive strategy remains questionable due to the senescence-associated secretory phenotype. Hence, studies and development of senolytic compounds that induce cell death in senescent cells have recently emerged. Senescent cells are hypothesized to exhibit different upregulated pro-survival/anti-apoptotic networks depending on the senescent inducers. This might limit the effect of a particular senolytic compound that targets rather only a specific pathway. Interestingly, cellular senescence in prostate cancer (PCa) cells can be induced by either androgen receptor (AR) agonists at supraphysiological androgen level (SAL) used in bipolar androgen therapy or by AR antagonists. This challenges to define ligand-specific senolytic compounds.
RESULTS: Here, we first induced cellular senescence by treating androgen-sensitive PCa LNCaP cells with either SAL or the AR antagonist Enzalutamide (ENZ). Subsequently, cells were incubated with the HSP90 inhibitor Ganetespib (GT), the Bcl-2 family inhibitor ABT263, or the Akt inhibitor MK2206 to analyze senolysis. GT and ABT263 are known senolytic compounds. We observed that GT exhibits senolytic activity specifically in SAL-pretreated PCa cells. Mechanistically, GT treatment results in reduction of AR, Akt, and phospho-S6 (p-S6) protein levels. Surprisingly, ABT263 lacks senolytic effect in both AR agonist- and antagonist-pretreated cells. ABT263 treatment does not affect AR, Akt, or S6 protein levels. Treatment with MK2206 does not reduce AR protein level and, as expected, potently inhibits Akt phosphorylation. However, ENZ-induced cellular senescent cells undergo apoptosis by MK2206, whereas SAL-treated cells are resistant. In line with this, we reveal that the pro-survival p-S6 level is higher in SAL-induced cellular senescent PCa cells compared to ENZ-treated cells. These data indicate a difference in the agonist- or antagonist-induced cellular senescence and suggest a novel role of MK2206 as a senolytic agent preferentially for AR antagonist-treated cells.
CONCLUSION: Taken together, our data suggest that both AR agonist and antagonist induce cellular senescence but differentially upregulate a pro-survival signaling which preferentially sensitize androgen-sensitive PCa LNCaP cells to a specific senolytic compound.

Keywords

Akt inhibitor Antiandrogen Bcl-2 family inhibitor Bipolar androgen therapy Cellular senescence HSP90 inhibitor Prostate cancer Senolytic compounds

References

Cancer Res. 2012 Sep 1;72(17):4483-93 [PMID: 22815528]
Lancet Oncol. 2018 Jan;19(1):76-86 [PMID: 29248236]
Annu Rev Pathol. 2010;5:99-118 [PMID: 20078217]
Int J Oncol. 2013 Jan;42(1):35-43 [PMID: 23152004]
CA Cancer J Clin. 2019 Jan;69(1):7-34 [PMID: 30620402]
World J Clin Oncol. 2018 Dec 20;9(8):180-187 [PMID: 30622926]
Endocr Relat Cancer. 2015 Oct;22(5):805-18 [PMID: 26187127]
Aging Cell. 2016 Jun;15(3):428-35 [PMID: 26711051]
Nature. 2014 Jan 2;505(7481):35-6 [PMID: 24352243]
Nature. 2005 Aug 4;436(7051):642 [PMID: 16079833]
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [PMID: 7568133]
Annu Rev Physiol. 2013;75:685-705 [PMID: 23140366]
Clin Cancer Res. 2015 Oct 1;21(19):4321-6 [PMID: 26106072]
Lab Invest. 2018 Dec;98(12):1575-1587 [PMID: 30206313]
Horm Mol Biol Clin Investig. 2012 Oct;11(1):321-8 [PMID: 25436691]
Oncogene. 2005 Jun 2;24(24):3954-63 [PMID: 15782121]
Mol Cancer Ther. 2010 Jul;9(7):1956-67 [PMID: 20571069]
Horm Behav. 2008 May;53(5):741-52 [PMID: 18067894]
Cancer Cell Int. 2005 Apr 06;5(1):8 [PMID: 15813967]
Nat Commun. 2017 Sep 4;8(1):422 [PMID: 28871086]
Mol Cancer. 2014 Sep 12;13:214 [PMID: 25216853]
Curr Biol. 2017 Sep 11;27(17):2652-2660.e4 [PMID: 28844647]
Int J Cancer. 2019 Apr 15;144(8):1775-1779 [PMID: 30125354]
Nucleic Acids Res. 2012 Nov;40(21):10765-79 [PMID: 23019221]
Cell Cycle. 2018;17(9):1048-1055 [PMID: 29886783]
Int Rev Cell Mol Biol. 2015;320:41-73 [PMID: 26614871]
Mol Endocrinol. 2014 Nov;28(11):1831-40 [PMID: 25203674]
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71 [PMID: 15784165]
PLoS One. 2016 Feb 26;11(2):e0149995 [PMID: 26919188]
J Steroid Biochem Mol Biol. 2019 Apr;188:59-70 [PMID: 30615932]
PLoS Biol. 2008 Dec 2;6(12):2853-68 [PMID: 19053174]
Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40 [PMID: 17667954]
Aging (Albany NY). 2017 Mar 8;9(3):955-963 [PMID: 28273655]
Oncotarget. 2015 Nov 3;6(34):35542-55 [PMID: 26325261]
Bioorg Med Chem. 2010 Oct 1;18(19):6960-9 [PMID: 20826091]
Methods Mol Biol. 2018;1857:35-51 [PMID: 30136228]
J Clin Oncol. 2011 Dec 10;29(35):4688-95 [PMID: 22025163]
Clin Adv Hematol Oncol. 2018 Jun;16(6):408-411 [PMID: 30067610]
PLoS One. 2012;7(3):e31052 [PMID: 22403609]
Prostate. 2019 Aug;79(11):1347-1359 [PMID: 31228231]
Oncogene. 2008 Jul 17;27(31):4344-52 [PMID: 18362888]
J Carcinog. 2011;10:20 [PMID: 21886458]
Transl Oncol. 2012 Dec;5(6):422-9 [PMID: 23323157]
J Mol Cell Biol. 2016 Jun;8(3):207-20 [PMID: 26993046]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [PMID: 17237035]
J Mol Med (Berl). 2016 Oct;94(10):1167-1179 [PMID: 27305909]
J Gene Med. 2002 Jul-Aug;4(4):397-406 [PMID: 12124982]
Br J Cancer. 2018 Oct;119(9):1118-1128 [PMID: 30377337]
Journal Article

Word Cloud

Similar Articles

Cited By